Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SLC9A3 | P48764 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25671670 | 1.00 | CDK5 (0.46) | CDK5CDK5R1L3MBTL1BCHECNR2 | |
| SCHEMBL25493962 | 0.86 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9AKDM4ERARB | |
| SCHEMBL21125363 | 0.86 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9AKDM4ERARB | |
| SCHEMBL17721292 | 0.86 | RAB9A (0.47) | L3MBTL1NPC1RAB9AKDM4ECYP2C9 | |
| Hydrochloric Acid SCHEMBL21531561 | 0.84 | RAB9A (0.46) | L3MBTL1NPC1RAB9AKDM4ECYP2C9 | |
| SCHEMBL25897953 | 0.82 | RARB (0.45) | L3MBTL1NPC1RAB9AKDM4ERARB | |
| SCHEMBL25898026 | 0.82 | RARB (0.45) | L3MBTL1NPC1RAB9AKDM4ERARB | |
| SCHEMBL25427287 | 0.80 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9AKDM4ERARB | |
| SCHEMBL17721288 | 0.80 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9AKDM4ERARB | |
| SCHEMBL25623340 | 0.80 | L3MBTL1 (0.51) | L3MBTL1NPC1RAB9AKDM4ERARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098695-A1 | ANTIBODY LABELING METHOD | 上海睿智医药研究集团有限公司 | 2026-05-15 | — | — | WO | claimed |
| CN-118546380-A | Biodegradable polymer, preparation method and application thereof, and medical filling material | 上海发微医用材料有限公司 | 2024-08-27 | — | — | CN | claimed |
| WO-2026098695-A1 | ANTIBODY LABELING METHOD | 上海睿智医药研究集团有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12454550-B2 | Compositions and methods for bioorthogonal surface coating | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4608454-A1 | SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION | Eli Lilly and Company (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025072355-A1 | METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO | BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4519385-A2 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024222483-A1 | ANTIBODY-CONJUGATED IMMUNO-ACTIVATING SMALL MOLECULE COMPOUND, AND USE | 深圳市康居正医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| CN-118546380-A | Biodegradable polymer, preparation method and application thereof, and medical filling material | 上海发微医用材料有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240191211-A1 | BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING | PROMEGA CORPORATION | 2024-06-13 | — | — | US | disclosed |
| WO-2024092219-A1 | SELF-HYDROLYZING MALEIMIDES FOR BIOCONJUGATION | ELI LILLY AND COMPANY (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230105381-A1 | COMPOSITIONS AND METHODS FOR BIOORTHOGONAL SURFACE COATING | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-06 | — | — | US | disclosed |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2022026915-A9 | ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411860-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLL, POLQ, POLB | CDK5 2304/4885CDK5R1 2630/4885L3MBTL1 1800/4885 |
| US-20230028388-A1 | DESIGN AND SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | RNGTT, POLRMT, MTR | CDK5 1923/4885CDK5R1 2106/4885L3MBTL1 497/4885 |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | CDK5 2716/4885CDK5R1 3265/4885L3MBTL1 349/4885 |
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | CDK5 1742/4885CDK5R1 2198/4885L3MBTL1 498/4885 |
| US-20230105381-A1 | COMPOSITIONS AND METHODS FOR BIOORTHOGONAL SURFACE COATING | TYR, TH, TDO2 | CDK5 1337/4885CDK5R1 1522/4885L3MBTL1 4525/4885 |
| US-12454550-B2 | Compositions and methods for bioorthogonal surface coating | TYR, TH, TDO2 | CDK5 1337/4885CDK5R1 1522/4885L3MBTL1 4525/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | CDK5 2908/4885CDK5R1 3491/4885L3MBTL1 430/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | CDK5 1742/4885CDK5R1 2198/4885L3MBTL1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.